Lucentis

Treat-and-extend protocol reduces burden of anti-VEGF treatment for DMEResults of the prospective TREX-DME study provide an evidence base for using a treat-and-extend protocol for administering anti-VEGF injections for eyes with diabetic macular edema.
Subretinal therapy offers promise of lighter treatment burden for AMDRGX-314 gene therapy offers patients the potential for a lower treatment burden with one subretinal injection of a gene therapy delivering an anti-vascular endothelial growth factor protein.
Outcomes differ from trials with ‘real-world’ anti-VEGF therapy for DMEThe visual outcomes after anti-VEGF therapy administered to treat diabetic macular edema in the “real world” do not achieve those reported in randomized clinical trials. Eyes with better baseline visual acuity are disproportionately affected.
Using OCT with your diabetes patientsOCT is one of the best way to assess patients for the presence of diabetic macular edema (DME)
10 highlights from AAO 2016
Anti-VEGF drugs: Safe and effective for treating DMEData from large randomized trials indicate that diabetic macular edema can be treated safely and effectively with anti-vascular endothelial growth factor therapies.
Combination anti-VEGF, navigated laser for DME on a par with monotherapyData show that the combination of navigated laser and anti-vascular endothelial growth factor (VEGF) compares favorably with anti-VEGF monotherapy.
Ranibizumab proves instrumental for DME patients in RIDE, RISE trialsRanibizumab provided improvements in visual acuity and DR that were stable over the long term when the drug was administered on an as-needed regimen to patients with diabetic macular edema in the RIDE and RISE trials.
FDA's Avastin rules may not be necessaryWhile FDA is proposing that bevacizumab (Avastin) for macular degeneration be used within 5 days of re-packaging to avoid development of endophthalmitis in patients, that precaution may not be necessary, according to a new study.
Novartis deterred UK physicians from prescribing Avastin, report saysNovartis attempted to block studies in the United Kingdom comparing ranibizumab (Lucentis) and bevacizumab (Avastin) for the treatment of wet age-related macular degeneration (AMD), according to an article published in The BJM, an international peer-reviewed medical journal.